The biggest innovation you can make is a better decision.
The Aetion Evidence Platform® (AEP) delivers real-world evidence for the manufacturers, purchasers, and regulators of medical treatments and technologies. We help you answer the high-stakes questions in health care: what works best, for whom, and when. Because better answers lead to better decisions.Learn more
Aetion acquires synthetic data trailblazer Replica Analytics
The acquisition will give Aetion customers the ability to tap into previously inaccessible, high utility, global health data to conduct transformational healthcare research.
Webinar: Understanding FDA’s 2021 RWE guidance
Join Aetion’s scientific and regulatory leaders for a webinar on Thursday, December 9. They’ll discuss FDA’s real-world evidence strategy and how recently released draft guidance documents impact the regulatory landscape.Register here
The Evidence Hub
Want to learn more about real-world evidence? Read up on perspectives, milestones, and best practices in real-world evidence and value-based health care on our blog, the Evidence Hub.Read more
Turn real-world data into real-world evidence.
AEP is scientifically validated software that analyzes data from the real world to produce transparent and rapid answers—on safety, effectiveness, and value—across the product lifecycle.
Scientific rigor for real-world evidence
As a partner to the majority of the top 20 global biopharma firms, leading payers, and regulators, Aetion informs the most critical decisions in the industry. Our transparent analyses guide product development, commercialization, and payment innovation.
Rapid answers for decisions that matter
AEP moves the application of real-world evidence from descriptive analytics to causal conclusions. And it delivers answers within days and weeks—the rapid results needed to improve clinical and financial outcomes. Turn your best available information into insights you can use now.
Trusted real-world evidence for all stakeholders
Our solutions begin with asking the right question and determining the right data from commercial and academic partners around the world. Then, the analytic workflows of the platform—meeting and setting international scientific standards—enable you to validate assumptions and align stakeholders.
Aetion Evidence Platform has been tremendous for us with regards to delivering RWE more efficiently. From an operational perspective, it has helped us generate high quality evidence faster, and allows us to deliver more for our stakeholders.
The most intriguing part of the Aetion story is the ability to have a very consistent analytic approach that can be applied across multiple data sets.
Aetion’s rapid turn-around time is critical, as is the fact that their analyses are based on our membership. By using predictive modeling to identify high-risk patients—who will become high-cost—we’re able to quickly engage with providers and health systems to intervene early. This improves outcomes for our highest-risk patient populations.
As part of our digital business transformation, we believe that strategic partnerships will advance our capabilities for rapid analytics. The Aetion Evidence Platform has helped reduce the completion time for UCB’s RWE initiatives by 50%, and has enhanced our capabilities to run multiple concurrent studies.
News & Events
News & Events
FDA, Aetion expand RWE work to focus on inpatient COVID-19 therapies
Real-world evidence: ‘Labor-intensive’ data standardization may be required by US FDA
Endpoints at JPM 2022
Commercializing novel disease-modifying categories
RWE and regulatory decisions
The Evidence Digest
Subscribe to our newsletter for insights and updates on research and applications for real-world evidence in life sciences and value-based health care.